Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 ...

Both Moderna and Pfizer/BioNTech announced that their respective vaccines would be available in the coming days.

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

Moderna, Inc.'s combination flu and COVID-19 vaccine, mRNA-1083, showed strong Phase 3 results in adults over 50. Pfizer/BioNTech's combination vaccine faced setbacks, giving Moderna a potential ...

The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...

BioNTech and US coronavirus jab rival Moderna, both of whose shares have slid about 80 per cent since their 2021 pandemic peaks, are betting on cancer vaccines to revive their fortunes.

Lekha Gupta GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech GSK Plc has halted development of its herpes simplex virus vaccine ...

As a summer wave of Covid-19 continues to hit the United States, the US Food and Drug Administration on Thursday signed off on updated Covid-19 vaccines from Moderna and Pfizer/BioNTech.